Wait, What? Administration Now Designates “Fair Pay and Safe Workplaces” as Not Economically Significant
Client Alert | 1 min read | 05.10.16
In a sign that the Obama Administration may be preparing to rush the publication of the FAR Council’s final rules implementing the “Fair Pay and Safe Workplaces” executive order so as to avoid timing problems associated with the Congressional Review Act, the White House’s Office of Information and Regulatory Affairs (responsible for reviewing the rules before sending them to the FAR Secretariat for publication, discussed here) now lists the new rules as not “Economically Significant.” That determination allows the administration to avoid the requirements under EO 12866 to provide a more detailed assessment of the likely benefits and costs of the regulatory action, but it reverses the administration’s prior designation of these burdensome new compliance and reporting obligations, and it seems at odds with the designation of other rules, such as “Serving Sizes of Foods That Can Reasonably Be Consumed at One Eating Occasion” and “Energy Efficiency Standards for Residential Dehumidifiers,” as Economically Significant.
Contacts
Insights
Client Alert | 4 min read | 09.15.26
GAO Indicates Reasonable Conflict of Interest Investigation Must Include Inquiry of Involved Firm
The U.S. Government Accountability Office’s (GAO) recent decision in Viderity Inc.—Costs, B-424422.5, Sept. 1, 2026, offers useful insight into what constitutes a legally sufficient conflict of interest investigation. The decision arose in an unusual procedural posture: Viderity initially protested, alleging that an agency evaluator had a personal conflict of interest. After the agency took corrective action, Viderity filed a cost entitlement claim requesting that GAO direct the agency to reimburse Viderity’s protest costs. In evaluating that claim, GAO assessed whether Viderity’s underlying protest ground was “clearly meritorious.”
Client Alert | 3 min read | 09.15.26
Client Alert | 7 min read | 09.14.26
AI in Life Sciences: Ten Legal Considerations and Risks of AI Use in Drug Discovery and Development
Client Alert | 6 min read | 09.14.26
Mental Health Parity Bulletin Restates Best Practices for Evaluating Compliance


